The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

Interleukin‐6 (IL‐6) is associated with prostate cancer morbidity. In several experimental models, IL‐6 has been reported to have anti‐apoptotic and pro‐angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti‐IL‐6 antibody which has been successfully applied in several models representing prostate cancer. This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer.

[1]  J. Pinski,et al.  Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[2]  Hugh M. Davis,et al.  Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma , 2010, Clinical Cancer Research.

[3]  G. Jenster,et al.  Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.

[4]  H. Kung,et al.  Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells , 2009, Clinical Cancer Research.

[5]  Sandra A. Moore,et al.  Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. , 2009, Blood.

[6]  Dietmar Fuchs,et al.  Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. , 2008, Endocrine-related cancer.

[7]  M. Rajendran,et al.  A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. , 2008, Endocrine-related cancer.

[8]  R. Dhir.  Stat3 Promotes Metastatic Progression of Prostate Cancer , 2009 .

[9]  W. Grant.  Vitamin D may reduce prostate cancer metastasis by several mechanisms including blocking Stat3. , 2008, The American journal of pathology.

[10]  T. Burke,et al.  Grb2 signaling in cell motility and cancer , 2008, Expert opinion on therapeutic targets.

[11]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[12]  B. Potter,et al.  17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer , 2008 .

[13]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[14]  D. Fuchs,et al.  The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 , 2007, Oncogene.

[15]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[16]  J. Bektic,et al.  Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328 , 2006, The Prostate.

[17]  Daniel W Lin,et al.  Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yi Lu,et al.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.

[19]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[20]  J. Pinski,et al.  Interleukin‐6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation , 2004, International journal of cancer.

[21]  M. Trikha,et al.  CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice , 2004, International journal of cancer.

[22]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[23]  G. Bartsch,et al.  An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. , 2004, European journal of cancer.

[24]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[26]  D. Fuchs,et al.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.

[27]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[28]  H. Klocker,et al.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[30]  E. Keller,et al.  Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice , 2001, The Prostate.

[31]  E. Keller,et al.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  H. Klocker,et al.  Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue , 2000, The Journal of pathology.

[33]  T. Chung,et al.  STAT3 mediates IL‐6‐induced growth inhibition in the human prostate cancer cell line LNCaP , 2000, The Prostate.

[34]  J. M. Lin,et al.  Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. , 2000, The Prostate.

[35]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[36]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[37]  F. Fauvel-Lafève,et al.  Stromal cells from human benign prostate hyperplasia produce a growth‐inhibitory factor for LNCaP prostate cancer cells, identified as interleukin‐6 , 1996, International journal of cancer.

[38]  J. Simons,et al.  Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.

[39]  Jean D. Wilson,et al.  Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells , 1991, Molecular and Cellular Endocrinology.

[40]  A. J. Garrett,et al.  CANCER XENOGRAFTS IN NUDE MICE , 1976, The Lancet.